Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.46 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | KCNA2 | P16389 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10319923 | 0.88 | CYP3A4 (0.57) | CYP3A4ALDH1A1MAPTHPGDCYP2A6 | |
| SCHEMBL6361059 | 0.80 | CYP3A4 (0.75) | CYP3A4ALDH1A1MAPTHPGDCYP2A6 | |
| SCHEMBL4187228 | 0.76 | CYP3A4 (0.80) | CYP3A4ALDH1A1MAPTHPGDCYP2A6 | |
| SCHEMBL6272567 | 0.74 | MAOA (0.54) | CYP3A4ALDH1A1MAPTHPGDKDM4E | |
| SCHEMBL20278630 | 0.73 | KCNA2 (0.56) | CYP3A4ALDH1A1MAPTHPGDKDM4E | |
| SCHEMBL7893642 | 0.71 | KCNA2 (0.58) | CYP3A4ALDH1A1MAPTHPGDKDM4E | |
| SCHEMBL31542614 | 0.70 | CYP3A4 (0.80) | CYP3A4ALDH1A1MAPTHPGDCYP2A6 | |
| SCHEMBL434686 | 0.70 | CYP3A4 (0.80) | CYP3A4ALDH1A1MAPTHPGDCYP2A6 | |
| Xanthotoxol SCHEMBL499269 | 0.69 | CYP3A4 (0.59) | CYP3A4ALDH1A1MAPTHPGDCYP2A6 | |
| SCHEMBL30226185 | 0.69 | CYP3A4 (0.65) | CYP3A4ALDH1A1MAPTHPGDCYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180169433-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES | IMMUNOLIGHT, LLC (US) | 2018-06-21 | — | — | US | disclosed |
| US-6187572-B1 | DECONTAMINATING BLOOD AND CELL CULTURES BY MIXING WITH A CHEMICAL RADIATION SENSITIZER WHICH DOES NOT BIND TO THE MEMBRANE, FREEZING OR FREEZE-DRYING THE MIXTURE, THEN EXPOSING TO ELECTROMAGNETIC RADIATION | BAXTER INTERNATIONAL INC. | 2001-02-13 | — | — | US | disclosed |
| US-5919935-A | Psoralen sensitizers for viral inactivation | THE OHIO STATE RESEARCH FOUNDATION (US) | 1999-07-06 | — | — | US | disclosed |
| WO-1998022468-A1 | PSORALEN SENSITIZERS FOR VIRAL INACTIVATION | OHIO STATE RESEARCH FOUNDATION (US) | 1998-05-28 | — | — | WO | disclosed |
| US-5587490-A | BINDING TO A PSORALEN COMPOUND | CREDIT MANAGERS ASSOCIATION OF CALIFORNIA (US) | 1996-12-24 | — | — | US | disclosed |
| US-5418130-A | Phosphonium or ammonium halo-psoralen | CRYOPHARM CORPORATION (US) | 1995-05-23 | — | — | US | disclosed |
| WO-1995002324-A1 | METHOD OF INACTIVATION OF VIRAL AND BACTERIAL BLOOD CONTAMINANTS | CRYOPHARM CORPORATION (US) | 1995-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180169433-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES | NFATC1, CDK10, PDCD10 | CYP3A4 2619/4885ALDH1A1 1556/4885MAPT 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.